NeuroMetrix (NSDQ:NURO) released preliminary data on Tuesday from a clinical study of its Quell wearable pain relief device for patients with chronic pain.
The study found that 81% of the patients reported improvements in chronic pain levels and overall health after 60-days of using the device, Waltham, Mass.-based NeuroMetrix said.
“We are pleased with these results. They represent the 1st formal evaluation of self-administered wearable intensive nerve stimulation. Quell provided substantial pain relief and improvement in quality of life measures. The primary outcome measure was impressive with 81% of subject’s rating Quell therapy as improving their chronic pain and overall health. We were not surprised that ⅔ of the subjects reduced their use of pain medications, as we have consistently received this anecdotal feedback from Quell users over the past several months. We look forward to completing data analyses and publishing the results,” CEO Dr. Shai Gozani said in a press release.
The average age of the patients tested was 56, and most had reported having chronic pain for 1-10 years, according to the company. At baseline, 40% of subjects reported severe pain, with the remaining reporting moderate pain.
Patients reported a 67% reduction in the use of pain medications, analyzed as a secondary outcome, and the largest measured changes reported were in pain relief and interference with sleep, general activity and walking ability.
Last week, NeuroMetrix said it signed a deal with supply chain company Advantage Consumer Healthcare to expand the distribution of its Quell wearable pain relief device. The new deal will position ACH to distribute the pain relief device to the retail sector, including mass merchandisers and chain drug stores, the company said.